EARLY ALZHEIMER'S DISEASE
Clinical trials for EARLY ALZHEIMER'S DISEASE explained in plain language.
Never miss a new study
Get alerted when new EARLY ALZHEIMER'S DISEASE trials appear
Sign up with your email to follow new studies for EARLY ALZHEIMER'S DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental Alzheimer's drug aims to lower brain 'Tangles' in Early-Stage patients
Disease control OngoingThis early-stage trial tests a drug called NIO752 in 38 people with mild Alzheimer's or mild cognitive impairment due to Alzheimer's. The drug is given as one or two injections into the spinal fluid to see if it can lower levels of tau protein, a key marker of Alzheimer's damage.…
Matched conditions: EARLY ALZHEIMER'S DISEASE
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising Alzheimer's drug lecanemab tested in 1,900 patients
Disease control OngoingThis study tests whether lecanemab can slow memory and thinking decline in people with early Alzheimer's disease. About 1,900 participants received either the drug or a placebo for 18 months, followed by an open-label extension where everyone can get lecanemab. The main goal is t…
Matched conditions: EARLY ALZHEIMER'S DISEASE
Phase: PHASE3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could a Synapse-Targeting drug slow Alzheimer's?
Disease control OngoingThis Phase 2 trial tests an experimental drug called CT1812 in 540 people with early Alzheimer's disease. Participants receive either the drug or a placebo for 18 months. The goal is to see if CT1812 can slow declines in memory, thinking, and daily function. The study is active b…
Matched conditions: EARLY ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: Cognition Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC